COVID-19 Vaccinations and Kidney Disease Outcomes - Dr. Christos Argyropoulos. скачать в хорошем качестве

COVID-19 Vaccinations and Kidney Disease Outcomes - Dr. Christos Argyropoulos.

Dr. Christos Argyropoulos, MD, PhD discusses the effects of vaccinations and infections—specifically COVID-19—on kidney disease outcomes, drawing from large-scale electronic health record analyses. Several studies were conducted to examine outcomes in both general and transplant populations, including rare and common kidney diseases, acute kidney injury (AKI), and thrombotic complications in dialysis patients. Key findings showed that COVID-19 infection is associated with increased risk of rare kidney diseases such as C3 glomerulopathy and IgA nephropathy, while vaccination showed minimal or no temporal association with these conditions. Similarly, repeated COVID-19 infections led to a higher rate of AKI and accelerated loss of kidney function, especially after the third infection, whereas vaccinations had no significant impact on kidney function decline. In dialysis patients, COVID-19 infection increased the risk of vascular access thrombosis, highlighting the disease’s thrombotic nature: • Rare Kidney Disease Findings: COVID-19 infection was associated with an increased risk of conditions like C3 glomerulopathy (C3GN) and Ig A nephropathy (IGAN), while vaccination showed minimal or no temporal association. • Common Kidney Disease Findings: Repeated COVID-19 infections led to higher rates of acute kidney injury and accelerated loss of kidney function, especially after the third infection; vaccinations did not significantly impact kidney function decline. • Thrombotic Complications: COVID-19 infection increased the risk of vascular access thrombosis in dialysis patients, highlighting the disease’s thrombotic nature. This complication was not found to increase with vaccination. The analysis supports the safety of COVID-19 vaccines for kidney patients, with infections posing a greater risk than vaccination. Overall, the evidence reinforces the public health benefit of vaccination in reducing kidney disease complications compared to infection. Health Watch USA meeting. Feb. 18, 2026.    • COVID-19 Vaccinations and Kidney Disease O...   Timeline of the Presentation 1:15 Objectives. 3:01 Study Methodology. 8:55 What is C3GN (Complement C3 Glomerulonephrophy). 10:55 Methodology for Evaluation of the relationship of COVID-19 and Vaccinations to C3GM. 11:49 The effects of vaccination and COVID infections on C3GN. 17:31 Complement also is implicated in Long COVID so the mechanism is plausible. 18:39 What is IgA Nephropathy (IGAN). 20:55 Five Phenotypes of IgA Nephropathy (IGAN). 22:37 Methodology for Evaluation of the relationship of COVID-19 and Vaccinations to IGAN. 22:56 The effects of vaccination and COVID infections on IGAN. 24:07 COVID-19 Vaccination and Gross Hematuria. 27:13 "our data suggests that if anything, infection is much worse than vaccination" 27:24 COVID 19 Infection and Vaccination and Primary Kidney Disease (CURE). 29:13 COVID-19 and Acute Kidney Injury (AKI). 31:22 Methodology of diagnosing AKI in Electronic Medical Record. 33:54 Patient Characteristics in AKI Study. 35:29 Frequency of AKI with Successive Number of Infections. 36:28 Vaccination was not observed to be associated with an increase in AKI. 38:50 "You see that a COVID positive test is probably associated with 40% higher risk of Acute Kidney Injury". 39:22 Will COVID-19 Impact the Future Development of Chronic Kidney Disease. 42:17 Summary of Data Regarding the Development of Chronic Kidney Disease. 45:34 "Vaccinations did not appear to change how fast one loses kidney function." 45:44 The impact of COVID-19 infections on the development of Kidney Disease. 46:55 The Clinical Significance of Hyperfiltration in Kidney Disease. 49:46 Thrombolic Effects in the Dialysis Population. 51:13 Vaccination versus infection in the risk of thrombotic events. 51:59 COVID-19 and Transplantation. 56:28 Summary and Caveats. 59:15 Final Thoughts and Healthcare Expenditures. 01:03:16 Need for immunotheraputics in kidney patients.